Johnson & Johnson said 58% of patients on ICOTYDE had an ACR20 response at Week 16, versus 41% on placebo, with no new safety signals. The stronger response supports the drug's prospects, though the report gives no approval decision.
That gives ICOTYDE stronger evidence as a possible treatment for psoriatic arthritis. More patients responded than on placebo, and the company reported no new safety signals. The report does not say whether regulators have approved the drug.
Follow Johnson & Johnson (JNJ) free. When we publish a story about it, you get the plain-English explanation as an alert.
Get alerts for JNJ